Menopausal hormone therapy in cancer survivors: A narrative review of the literature

Carol L. Kuhle, Ekta Kapoor, Richa Sood, Jacqueline M. Thielen, Aminah Jatoi, Stephanie S. Faubion

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex, and includes assessment of its impact on disease-free or overall survival. Estrogen receptors are present in several cancer types, but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes. Estrogen may even be protective against certain cancers. Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types, but not others. We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of breast, gynecologic, lung, colorectal, hematologic cancers, and melanoma. Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types (e.g., colorectal and hematologic cancer, localized melanoma, and most cervical, vulvar and vaginal cancers), while nonhormonal treatment options may be preferred for others (e.g., breast cancer). In women with other cancer types, recommendations are less straightforward, and the use of MHT must be individualized.

Original languageEnglish (US)
Pages (from-to)86-96
Number of pages11
JournalMaturitas
Volume92
DOIs
StatePublished - Oct 1 2016

Fingerprint

Survivors
Hormones
Neoplasms
Estrogens
Therapeutics
Estrogen Receptors
Colorectal Neoplasms
Melanoma
Tumors
Vaginal Neoplasms
Vulvar Neoplasms
Decision making
Recurrence
Mortality
Uterine Cervical Neoplasms
Decision Making
Breast
Breast Neoplasms
Lung
Survival

Keywords

  • Estrogen
  • Hormonal influence
  • Hormone therapy
  • Hot flashes
  • Menopausal hormone therapy
  • Menopause
  • Progestin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Obstetrics and Gynecology

Cite this

Menopausal hormone therapy in cancer survivors : A narrative review of the literature. / Kuhle, Carol L.; Kapoor, Ekta; Sood, Richa; Thielen, Jacqueline M.; Jatoi, Aminah; Faubion, Stephanie S.

In: Maturitas, Vol. 92, 01.10.2016, p. 86-96.

Research output: Contribution to journalReview article

Kuhle, Carol L. ; Kapoor, Ekta ; Sood, Richa ; Thielen, Jacqueline M. ; Jatoi, Aminah ; Faubion, Stephanie S. / Menopausal hormone therapy in cancer survivors : A narrative review of the literature. In: Maturitas. 2016 ; Vol. 92. pp. 86-96.
@article{6272b5efbe9a496e8b79be6fd85f43ac,
title = "Menopausal hormone therapy in cancer survivors: A narrative review of the literature",
abstract = "Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex, and includes assessment of its impact on disease-free or overall survival. Estrogen receptors are present in several cancer types, but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes. Estrogen may even be protective against certain cancers. Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types, but not others. We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of breast, gynecologic, lung, colorectal, hematologic cancers, and melanoma. Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types (e.g., colorectal and hematologic cancer, localized melanoma, and most cervical, vulvar and vaginal cancers), while nonhormonal treatment options may be preferred for others (e.g., breast cancer). In women with other cancer types, recommendations are less straightforward, and the use of MHT must be individualized.",
keywords = "Estrogen, Hormonal influence, Hormone therapy, Hot flashes, Menopausal hormone therapy, Menopause, Progestin",
author = "Kuhle, {Carol L.} and Ekta Kapoor and Richa Sood and Thielen, {Jacqueline M.} and Aminah Jatoi and Faubion, {Stephanie S.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.maturitas.2016.07.018",
language = "English (US)",
volume = "92",
pages = "86--96",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Menopausal hormone therapy in cancer survivors

T2 - A narrative review of the literature

AU - Kuhle, Carol L.

AU - Kapoor, Ekta

AU - Sood, Richa

AU - Thielen, Jacqueline M.

AU - Jatoi, Aminah

AU - Faubion, Stephanie S.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex, and includes assessment of its impact on disease-free or overall survival. Estrogen receptors are present in several cancer types, but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes. Estrogen may even be protective against certain cancers. Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types, but not others. We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of breast, gynecologic, lung, colorectal, hematologic cancers, and melanoma. Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types (e.g., colorectal and hematologic cancer, localized melanoma, and most cervical, vulvar and vaginal cancers), while nonhormonal treatment options may be preferred for others (e.g., breast cancer). In women with other cancer types, recommendations are less straightforward, and the use of MHT must be individualized.

AB - Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex, and includes assessment of its impact on disease-free or overall survival. Estrogen receptors are present in several cancer types, but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes. Estrogen may even be protective against certain cancers. Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types, but not others. We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of breast, gynecologic, lung, colorectal, hematologic cancers, and melanoma. Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types (e.g., colorectal and hematologic cancer, localized melanoma, and most cervical, vulvar and vaginal cancers), while nonhormonal treatment options may be preferred for others (e.g., breast cancer). In women with other cancer types, recommendations are less straightforward, and the use of MHT must be individualized.

KW - Estrogen

KW - Hormonal influence

KW - Hormone therapy

KW - Hot flashes

KW - Menopausal hormone therapy

KW - Menopause

KW - Progestin

UR - http://www.scopus.com/inward/record.url?scp=84982685804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982685804&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2016.07.018

DO - 10.1016/j.maturitas.2016.07.018

M3 - Review article

C2 - 27621244

AN - SCOPUS:84982685804

VL - 92

SP - 86

EP - 96

JO - Maturitas

JF - Maturitas

SN - 0378-5122

ER -